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Vitamin D receptor is a trans-acting transcriptional
factor that mediates 1a,25-dihydroxyvitamin D3 action
in the regulation of target gene expression. Recent
studies have shown that clinical response of psoriasis
to 1a,25-dihydroxyvitamin D3 is correlated with the
vitamin D receptor mRNA expression level, which
may be influenced by the genotype of the vitamin D
receptor. In this study, we have explored a possible
association between psoriasis and the polymorphism
in the gene encoding the vitamin D receptor. We
examined the allelic frequencies of the vitamin D
receptor in psoriasis patients (n J 104) and in healthy
controls (n J 104) by analyzing the restriction pattern
of the polymerase chain reaction products. A signifi-
cant increase in the frequency of the A allele (absence
of the restriction site at intron 8) by ApaI restriction
Psoriasis is a common and persistent papulosquamousdisease of unknown etiology, which affects up to 2%of the population (Krueger et al, 1984). It is characterizedby hyperproliferation of the keratinocytes and inflam-mation. The therapeutic efficacy of 1α,25-dihydroxyvi-
tamin D3 [1,25(OH)2D3] and its analogs has been tested and proved
to be effective for the treatment of psoriasis (Kragballe et al, 1991).
1,25(OH)2D3 is the endogenously produced, hormonally active
form of vitamin D3. In addition to the known effect of 1,25(OH)2D3
on controlling calcium and bone metabolism (Reichel et al, 1989),
it inhibits proliferation and induces terminal differentiation of
cultured human keratinocytes (Smith et al, 1986), and can also
modulate the immune system in a variety of ways. 1,25(OH)2D3
elicits its action on target tissues through the vitamin D receptor
(VDR). The VDR is a member of the steroid/thyroid hormone
receptor superfamily, which is a group of ligand-dependent tran-
scription factors. The receptor-hormone complex binds to hormone
response elements in regulatory regions of target genes, and
modulates the gene transcription. It has been noted, however, that
cultured fibroblasts and keratinocytes from some psoriatic patients
have partial resistance to 1,25(OH)2D3 mediated anti-proliferative
activity (MacLaughlin et al, 1985; Smith et al, 1988). Furthermore,
Manuscript received June 15, 1998; revised September 8, 1998; accepted
for publication September 28, 1998.
Reprint requests to: Dr. In-Gyu Kim, Department of Biochemistry and
Molecular Biology, Seoul National University College of Medicine, 28
Yongon-Dong Chongno-Gu, Seoul 110–799, Korea.
Abbreviations: 1,25(OH)2D3, 1α,25-dihydroxyvitamin D3; VDR,
vitamin D receptor.
0022-202X/99/$10.50 · Copyright © 1999 by The Society for Investigative Dermatology, Inc.
113
fragment length polymorphism was observed in psori-
asis patients compared with that of the control group,
and the tendency was more accentuated in early onset
psoriasis. Odds ratios (95% confidence interval) for
psoriasis of AA and Aa genotypes were 5.0 (1.3–19.1)
and 2.4 (1.3–4.3), and odds ratios for early onset of
AA and Aa genotypes were 6.4 (1.6–25.0) and 3.1 (1.7–
5.9), respectively. Allele frequencies for A and a alleles
were 0.317 and 0.683 in the psoriasis group and 0.168
and 0.832 in the control group (p J 0.001). A signific-
ant association between vitamin D receptor genotypes
and the mean age at onset was observed (p < 0.05).
Our findings suggest that allelic variance in the vitamin
D receptor gene itself or other genes in linkage
disequilibrium with this gene, could predispose to the
development of psoriasis. J Invest Dermatol 112:113–
116, 1999
clinical response to 1,25(OH)2D3 treatment is variable in patients
with psoriasis. It has been shown that the intracellular level of
VDR protein correlates with the cellular response to 1,25(OH)2D3
in cultured human colon cancer cell line (Zhao and Feldman,
1993), and altered induction of VDR mRNA in the treated
psoriatic plaques is a marker for clinical responsiveness to
1,25(OH)2D3 treatment (Chen et al, 1996).
Recently, it has been reported that allelic variations of the VDR
gene are associated with the risk of developing prostate cancer in
men and osteoporosis in post-menopausal women (Morrison et al,
1994; Taylor et al, 1996). The polymorphism of the VDR gene
can predict the differences in bone density, accounting for up to
75% of the total genetic effect on bone density in healthy individuals
(Morrison et al, 1994). Although it was suggested that cDNA
differences in the 39 untranslated region of each VDR genotype
may alter VDR mRNA levels (Morrison et al, 1994), the molecular
mechanisms by which bone density is regulated by the VDR gene
are not fully understood. The 39 untranslated region polymorphisms
are in strong linkage disequilibrium with restriction fragment length
polymorphisms (RFLP) located in intron 8 (BsmI and ApaI) and
exon 9 (TaqI). Conflicting results have ensued concerning the
association of the BsmI RFLP in the VDR gene and bone density
(Eisman, 1995). Despite the controversy, the physiologic parameters
that are regulated by 1,25(OH)2D3, such as serum osteocalcin level
and calcium absorption, are found to be correlated with VDR
genotype (Morrison et al, 1992; Dawson-Hughes et al, 1995). These
results suggest that genetic polymorphism of the VDR gene may
influence 1,25(OH)2D3 mediated normal physiologic response of
keratinocytes and can explain the variable responsiveness.
Although an association between VDR genotype and clinical
response to 1,25(OH)2D3 or its analogs is not yet clear (Holick
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et al, 1996; Kontula et al, 1997), the variable inducibility or stability
of VDR mRNA by 1,25(OH)2D3 may reflect the heterogeneity
in VDR genotype. Thus, the complexity of VDR genotype and
variable responsiveness to 1,25(OH)2D3 treatment provide a basis
to test whether VDR gene may be one of the susceptibility genes
for psoriasis. Recent studies have found a strong genetic background
for psoriasis (Elder et al, 1994a). Although genome-wide searches
for linked genes in affected families have come up with several
chromosome regions cosegregating with the disease, the strongest
association has been established for genes of the major histocompat-
ibility complex or other related genes (Hoehler et al, 1997). Psoriasis
shows a polygenic or multifactorial pattern of inheritance, the latter
term distinguished by the additional involvement of environmental
factors. The high heritability of the disease and studies indicating
that susceptibility alleles can be inherited from parents with no
personal or family history of psoriasis, lends support to the conten-
tion that one or more additional genes, not necessarily linked to
the HLA locus, is a determinant of psoriasis susceptibility (Elder
et al, 1994a; Henseler, 1997).
In this study, we report that the VDR polymorphism is associated
with psoriasis by comparing the allele frequencies of VDR genotypes
in psoriasis patients with those of normal healthy controls.
MATERIALS AND METHODS
Patients One hundred and four unrelated psoriasis patients, 52 men and
52 women aged 8–73 y (mean age, 37.1 6 15.3 y), were recruited
randomly from the Department of Dermatology, Seoul National University
Hospital, for this study. All patients had psoriasis vulgaris with a duration
of 0.1–41 y (mean duration, 12.2 6 9.7 y). The age at onset of psoriasis
ranged from 5 to 71 y old (mean age at onset, 24.9 6 14.6 y). The patient
group included 86 patients with early onset (onset not later than at the
age of 40 y). All the patients were clinically evaluated concerning their
family history of psoriasis, nail involvement, psoriatic arthropathy, and
psoriasis area and severity index score. The normal control population
consisted of 104 unrelated, healthy persons. All control subjects and psoriasis
patients enrolled in this study had ethnic Korean background.
VDR genotyping The genomic DNA was extracted from leukocytes
using standard methods (Sambrook et al, 1989). The VDR gene was
amplified by using hemi-nested polymerase chain reaction (PCR). For
detection of ApaI and TaqI sites, primer 1 (59-CAGAGCATGGA-
CAGGGAGCAAG-39) in intron 8, and primer 2 (59-GCAACTCCT-
CATGGCTGAGGTCTCA-39) and primer 3 (59-AGGGGTTAGG-
TTGGACAGGAGAGAG-39) in exon 9 were used. For detection of BsmI
site, primer 1 (59-CAACCAAGACTACAAGTACCGCGTCAGTGA-39)
in exon 7, primer 2 (59-TGGCGGCAGCGGATGTACGTCTGC-39) in
exon 9, and primer 3 (59-AACCAGCGGGAAGAGGTCAAGGG-39) in
intron 8 were used (Morrison et al, 1994).
First PCR product was obtained using primers 1 and 2 with genomic
DNA. Second PCR product was obtained using primers 1 and 3 with first
PCR product. Each sample was subjected to 35 cycles in a DNA thermal
cycler (Perkin Elmer Cetus, Norwalk, CT). After organic extraction of
the second PCR product, the products were digested with respective
restriction enzymes (New England Biolabs, Beverly, MA) according to the
manufacturer’s instructions. The digested samples were size fractionated by
electrophoresis in a 1% agarose gel. Visualization after ethidium bromide
staining was performed by means of ultraviolet fluorescence. Gels were
photographed using a Polaroid MP-4 camera (Clifton, NJ) and analyzed
for RFLP. The RFLP were coded as Aa (ApaI), Tt (TaqI), or Bb (BsmI),
where a uppercase letter signifies absence of the site and a lowercase letter
signifies presence of the site. DNA analysis was performed blind to
clinical data.
Statistical analysis Differences in the VDR genotypes were compared
between psoriasis patients and controls by chi square test. Differences in
the VDR genotypes were compared between early onset psoriasis patients
and controls by Fisher’s exact test. The VDR allele frequencies were
deduced from genotype frequencies on the basis of Hardy–Weinberg
equilibrium, and the case-control differences in the allele frequencies were
also statistically analyzed with chi square test. Odds ratios were calculated
with 95% confidence intervals. One-way analysis of variance test was used
to compare group means of age at onset in the AA, Aa, and aa genotype
groups. Chi square test was performed in the analysis of associations
between other clinical variables and VDR genotypes, and in the analysis
Figure 1. ApaI RFLP of the VDR gene. Genomic DNA was amplified
using hemi-nested PCR method. The 689 bp second PCR product was
digested with ApaI enzyme and size fractionated by 1% agarose gel
electrophoresis. AA or aa denote the homozygote for the absence or
presence of the ApaI site, respectively. Aa denotes the heterozygote. M,
DNA size marker, φ174 HaeIII digest.
Table I. Distribution of the VDR ApaI genotypes among
psoriasis patients and controls, and odds ratios for
psoriasis
Genotype Controls All psoriasis Early onsetc
(n 5 104)a (n 5 104) (n 5 86)
Frequency
AA 3 (2.9%) 10 (9.6%) 9 (10.5%)
Aa 29 (27.9%) 46 (44.2%) 43 (50.0%)
aa 72 (69.2%) 48 (46.2%) 34 (39.5%)
Odds ratio [95% CI]b
AA/aa 1.0 5.0 [1.3–19.1] 6.4 [1.6–25.0]
Aa/aa 1.0 2.4 [1.3–4.3] 3.1 [1.7–5.9]
an, number of investigated subjects.
bCI, confidence interval.
cOnset not later than at the age of 40 y.
of sexual difference in VDR genotypes. The p value less than 0.05 was
regarded as statistically significant.
RESULTS
Psoriasis patients showed significantly different ApaI RFLP
VDR genotypes and allele frequencies 740 bp and 1850 bp
first PCR product were obtained using primers 1 and 2 for ApaI
and TaqI sites, and for the BsmI site, respectively. Then, 689 bp
and 825 bp second PCR products were obtained using primers 1
and 3, respectively. In each subject, the VDR genotypes were
identified after restriction enzyme digestion of the second PCR
product. In the psoriasis group, the frequencies for the BB, Bb,
and bb genotypes were 1.8%, 5.5%, and 92.7%, respectively, and
the frequencies for the TT, Tt, and tt genotypes were 94.5%, 5.5%,
and 0.0%, respectively. Compared with the control group, no
significant differences were observed for BsmI and TaqI RFLP
genotype frequencies.
In contrast, the significant difference in frequencies for ApaI
RFLP genotype was observed between the psoriasis group and the
control group. Digestion of the PCR segment with ApaI resulted
in three genotypes: in the AA type only the 689 bp band was
present; the Aa type included 689, 478, and 211 bp bands; and the
aa type included 478 and 211 bp bands (Fig 1). Frequencies for
AA, Aa, and aa genotypes were 10 (9.6%), 46 (44.2%), and 48
(46.2%) in the psoriasis group, and three (2.9%), 29 (27.9%), and
72 (69.2%) in the control group, respectively. We found a significant
increase in subjects carrying AA and Aa genotypes in psoriasis
patients (Table I). In addition, this tendency was more accentuated
in the psoriasis patients with early onset. Odds ratios (95%
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Figure 2. Age at onset and ApaI RFLP of the VDR gene. The
distributions of age at onset in individuals with aa (n 5 48), Aa (n 5 46),
and AA (n 5 10) genotypes in psoriasis patients. Solid vertical bars indicate
mean 6 SD for each group (*p 5 0.05, **p , 0.01).
Table II. Allele frequencies in controls and psoriasis
patients
Allele frequency
Odds ratio
A a [95% CI]b p
All psoriasis (n 5 104)a 0.317 0.683 2.3 [1.4–3.7] 0.001
Early onset (n 5 86)c 0.354 0.645 2.7 [1.7–4.4] ,0.001
Controls (n 5 104) 0.168 0.832 1.0
an, number of investigated subjects.
bCI, confidence interval.
cOnset not later than at the age of 40 y.
confidence interval) for psoriasis of AA and Aa genotypes were
5.0 (1.3–19.1) and 2.4 (1.3–4.3), respectively. Odds ratios (95%
confidence interval) for early onset of AA and Aa genotypes
were 6.4 (1.6–25.0) and 3.1 (1.7–5.9), respectively. Derived allele
frequencies for A and a alleles were 0.317 and 0.683 in the psoriasis
group and 0.168 and 0.832 in the control group (Table II). Allele
frequency for carrying A increased to 0.354 in the early onset
psoriasis group. Haplotype analysis of BsmI, TaqI, and ApaI RFLP
was not possible due to absence of parental genotypes in this study.
No sexual difference in VDR genotype We have evaluated
whether there is any sexual difference in the VDR genotypes. The
frequencies for AA, Aa, and aa genotypes were seven (13.5%), 21
(40.4%), and 24 (46.1%) in the 52 male psoriasis patients, and three
(5.8%), 25 (48.1%), and 24 (46.1%) in the 52 female psoriasis
patients, respectively. There was no significant difference in VDR
genotypes between male and female psoriasis patients.
Significant correlation between age at onset and VDR
genoypes Means of age at onset, defined by the VDR poly-
morphism in the psoriasis patients, were compared among the three
groups. Mean age at onset was 29.3 6 17.2 (n 5 48), 21.5 6 11.1
(n 5 46), and 19.1 6 10.2 (n 5 10) y old for homozygotes aa,
heterozygotes Aa, and homozygotes AA, respectively, showing a
significant relationship between VDR polymorphism and age at
onset of psoriasis (p , 0.05) (Fig 2); however, other clinical
variables such as family history of psoriasis, nail involvement,
psoriatic arthropathy, and psoriasis area and severity index score,
did not show any relationship with the VDR polymorphism (data
not shown).
DISCUSSION
This study shows that there is a significant difference in allele
frequencies and VDR genotypes between normal controls and
psoriasis patients, especially with early onset. This suggests that
allelic variance in VDR or genes in linkage disequilibrium with
the VDR gene, may be a risk factor for development of psoriasis.
Epidemiologic and clinical studies have shown that the peak age
of onset for psoriasis is bimodally distributed. Early onset psoriasis
is associated with a more severe and recurrent course, and increased
inheritability in Caucasians (Henseler and Christophers, 1985). This
tendency also applies to Koreans (manuscript in preparation). In
this study, the more increased odds ratio of having AA or Aa alleles
in the early onset group, and the significant difference in the mean
age at onset among the three VDR genotype groups, underlies the
significance of VDR polymorphism. Dominant genetic effect of
carrying allele A was suggested by the excess of heterozygotes
(Thomson and Bodmer, 1977). Kontula et al (1997) have previously
shown that there is no difference in allelic variation of the BsmI
site in intron 8 of the VDR gene between psoriasis patients and
controls. The apparent discrepancy between their results and ours
may be explained by the fact that the size of the population was
smaller, and that vitamin D responsiveness, rather than presence or
absence of disease, was investigated in that study. Also, a different
restriction site, e.g., BsmI genotype, was examined in that study.
Allelic variances in interleukin-1 receptor antagonist gene and
tumor necrosis factor-α gene, as well as numerous HLA loci, were
reported to be associated with psoriasis (Hoehler et al, 1997; Tarlow
et al, 1997). Based upon the current clinical and genetic knowledge,
psoriasis patients may show heterogeneous genetic make up (Elder
et al, 1994b; Ortonne, 1996). Lack of absolute difference in VDR
genotypes between psoriasis and normal controls further supports
the heterogeneity of cause. There may be several other factors
contributing to these relative differences: e.g., interaction of the
VDR gene alleles with the environment or with other genes.
Linkage disequilibrium to a nearby gene could also explain the
lack of absolute difference between cases and controls.
It is unknown whether psoriasis is related with an intrinsic
abnormality of the vitamin D3 signaling pathway, and vitamin D3
analogs improve psoriasis by overcoming an intrinsic abnormality
of the vitamin D3 signaling pathway in psoriatic skin (Kragballe,
1997). As the VDR mRNA levels may be influenced by the allelic
variance of VDR (Morrison et al, 1994), the allelic differences
between psoriasis and normal controls in this study may suggest
the differences in the VDR mRNA levels; however, the VDR
mRNA and protein levels were found to be similar between
normal skin and involved and uninvolved psoriatic skin (Sφlvsten
et al, 1996). These results indicate that the quantity of the VDR
mRNA or protein may not be the only explanation for variable
responsiveness to 1,25(OH)2D3 or the role of the VDR gene in
the pathogenesis of psoriasis. The other possible explanations could
be obtained from the studies of functional difference of VDR in
relation to VDR genotype. These include interaction with other
receptors and affinity for the target gene(s) that especially modulate
the immune function.
The observed associations, which are not quite as strong,
however, suggest another possible interpretation. Because associ-
ation studies test the correlated occurrence of disease and an allele
in a population, the population characteristics, such as population
admixture in an ancient Korean population, could result in positive
association of VDR polymorphism with psoriasis (Lander and
Schork, 1994). This spurious association could arise if psoriasis-
causing genes as well as allele A of the VDR gene happen to be
more common in the tested Korean population. Therefore, further
studies on this association, such as a transmission disequilibrium
test, will be required to exclude this possibility (Spielman et al, 1993).
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In conclusion, we report an association of a polymorphism in
the VDR gene with psoriasis. This suggests that the VDR gene
can be one of some candidate genes implicated in the pathogenesis
of psoriasis in the Korean population. We cannot completely rule
out the possibility that the association could represent population
stratification, because a transmission disequilibrium test was not
performed. It has already been revealed that there is a marked
ethnic difference in the VDR genotypes (Tokita et al, 1996).
It remains to be elucidated whether this polymorphism in the
pathogenesis of psoriasis is also applicable to other ethnic groups.
Further explanation of the molecular biologic or physiologic
mechanism upon the basis of the VDR genotypes should be
investigated.
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